SIMPLIFIED ALGORITHM FOR TREATMENT ELIGIBILITY: THE SLATE STUDY

计划入组 960 人

Stereotactic Laser Ablation for Temporal Lobe Epilepsy (Slate)

计划入组 167 人 · 首次发布于 2016 年 7 月 26 日

Compined Lumber Longissimus Plane Block and Multifidus Longissimus Plane Block Versus Infiltration Field Block in Lumber Spine Surgery

计划入组 50 人 · 首次发布于 2026 年 7 月 2 日

GRT-C903

AS-Probionorm(Industrial Microbiology LLP)

Cu-64-LLP2A

Slate Run Pharmaceuticals, LLC

United States

SLATE PHARMACEUTICALS INC

United States

CBCC Global Research LLP

India

ESSA Pharma Amends XenoTherapeutics Agreement, Reduces Shareholder Payout to $0.12 Per Share

Eli Lilly Acquires SiteOne Therapeutics for Up to $1 Billion to Advance Non-Opioid Pain Treatment

ESSA Pharma Agrees to $1.91 Per Share Acquisition by XenoTherapeutics in Wind-Down Transaction